Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study
Annals of Clinical and Translational Neurology, 2021 Objective Neuroinflammation is an important pathogenic mechanism in amyotrophic lateral sclerosis (ALS), with regulatory T cells (Tregs) mediating a slower rate of disease progression.
Steve Vucic +6 more
doaj +1 more source
Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis [PDF]
Farmacia Hospitalaria, 2021 Objective: Dimethyl fumarate is a medication approved for the treatment of relapsing-remitting multiple sclerosis. The purpose of the study was to evaluate the safety and persistence of dimethyl fumarate in clinical practice and analyze the ...
Silvia Boullosa-Lale +3 more
doaj +1 more source
Dimethyl Fumarate Alleviates Dextran Sulfate Sodium-Induced Colitis, through the Activation of Nrf2-Mediated Antioxidant and Anti-inflammatory Pathways. [PDF]
, 2020 Oxidative stress and chronic inflammation play critical roles in the pathogenesis of ulcerative colitis (UC) and inflammatory bowel diseases (IBD). A previous study has demonstrated that dimethyl fumarate (DMF) protects mice from dextran sulfate sodium ...
Farzaneh, Ted +8 more
core +2 more sources
Frontiers in Medicine, 2022 Psoriasis vulgaris is a chronic inflammatory skin disease characterized by well-demarcated scaly plaques. Oxidative stress plays a crucial role in the psoriasis pathogenesis and is associated with the disease severity.
Elena Campione +16 more
doaj +1 more source
Dimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal Protection. [PDF]
PLoS ONE, 2015 Dimethyl fumarate is an immunomodulatory and neuroprotective drug, approved recently for the treatment of relapsing-remitting multiple sclerosis. In view of the limited therapeutic options for human acute and chronic polyneuritis, we used the animal ...
Kalliopi Pitarokoili +4 more
doaj +1 more source
Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective. [PDF]
PLoS ONE, 2016 The paper aimed to estimate the incremental cost-effectiveness ratio (ICER) at the public published price for delayed-release dimethyl fumarate versus relevant Multiple Sclerosis disease-modifying therapies available in France in June 2015.The economic ...
Julie Chevalier +3 more
doaj +1 more source
Drug-Repurposing Strategy for Dimethyl Fumarate
Pharmaceuticals, 2023 In the area of drug discovery, repurposing strategies represent an approach to discover new uses of approved drugs besides their original indications.
Salvatore Giunta +8 more
doaj +1 more source
A Drug Combination Rescues Frataxin-Dependent Neural and Cardiac Pathophysiology in FA Models
Frontiers in Molecular Biosciences, 2022 Friedreich’s ataxia (FA) is an inherited multisystemic neuro- and cardio-degenerative disorder. Seventy-four clinical trials are listed for FA (including past and present), but none are considered FDA/EMA-approved therapy.
Rosella Abeti +7 more
doaj +1 more source
Klotho pathways, myelination disorders, neurodegenerative diseases, and epigenetic drugs [PDF]
, 2020 In this review we outline a rationale for identifying neuroprotectants aimed at inducing endogenous Klotho activity and expression, which is epigenetic action, by definition. Such an approach should promote remyelination and/or stimulate myelin repair by
Chen, Xiaohong +15 more
core +1 more source
JID Innovations, 2021 Dimethyl fumarate (DMF) is an effective oral treatment for psoriasis administered in Europe for nearly 60 years. However, its potential has been limited by contact dermatitis that prohibits topical application.
Krzysztof Bojanowski +4 more
doaj +1 more source